Matinas biopharma prices $10 million registered direct offering

Bedminster, n.j., april 03, 2024 (globe newswire) -- matinas biopharma holdings, inc. (nyse american: mtnb) (“matinas biopharma” or the “company”), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (lnc) platform delivery technology, today announced it has entered into securities purchase agreements with healthcare-focused institutional investors for the purchase and sale of 33,333,334 shares of common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 33,333,334 shares of common stock, at a combined offering price of $0.30 per share and accompanying warrant, pursuant to a registered direct offering. the warrants will have an exercise price of $0.35 per share, will be exercisable commencing six months from the date of issuance and will expire five and one-half years following the date of issuance.
MTNB Ratings Summary
MTNB Quant Ranking